JP2024521408A5 - - Google Patents

Info

Publication number
JP2024521408A5
JP2024521408A5 JP2023575753A JP2023575753A JP2024521408A5 JP 2024521408 A5 JP2024521408 A5 JP 2024521408A5 JP 2023575753 A JP2023575753 A JP 2023575753A JP 2023575753 A JP2023575753 A JP 2023575753A JP 2024521408 A5 JP2024521408 A5 JP 2024521408A5
Authority
JP
Japan
Prior art keywords
seq
amino acid
acid sequence
polypeptide chain
polypeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023575753A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024521408A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2022/065514 external-priority patent/WO2022258673A1/en
Publication of JP2024521408A publication Critical patent/JP2024521408A/ja
Publication of JP2024521408A5 publication Critical patent/JP2024521408A5/ja
Pending legal-status Critical Current

Links

JP2023575753A 2021-06-09 2022-06-08 Cd20、nkp46、cd16に結合し、かつil-2にコンジュゲートされた多特異性抗体 Pending JP2024521408A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163208514P 2021-06-09 2021-06-09
US63/208,514 2021-06-09
PCT/EP2022/065514 WO2022258673A1 (en) 2021-06-09 2022-06-08 Multispecific antibodies binding to cd20, nkp46, cd16 and conjugated to il-2

Publications (2)

Publication Number Publication Date
JP2024521408A JP2024521408A (ja) 2024-05-31
JP2024521408A5 true JP2024521408A5 (cg-RX-API-DMAC7.html) 2025-06-16

Family

ID=82214258

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023575753A Pending JP2024521408A (ja) 2021-06-09 2022-06-08 Cd20、nkp46、cd16に結合し、かつil-2にコンジュゲートされた多特異性抗体

Country Status (11)

Country Link
US (1) US20250002601A1 (cg-RX-API-DMAC7.html)
EP (1) EP4351733A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024521408A (cg-RX-API-DMAC7.html)
KR (1) KR20240019786A (cg-RX-API-DMAC7.html)
CN (1) CN117529504A (cg-RX-API-DMAC7.html)
AU (1) AU2022288574A1 (cg-RX-API-DMAC7.html)
BR (1) BR112023025476A2 (cg-RX-API-DMAC7.html)
CA (1) CA3227227A1 (cg-RX-API-DMAC7.html)
IL (1) IL308531A (cg-RX-API-DMAC7.html)
MX (1) MX2023014645A (cg-RX-API-DMAC7.html)
WO (1) WO2022258673A1 (cg-RX-API-DMAC7.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111201030B (zh) 2017-07-25 2024-11-01 真和制药有限公司 通过阻断tim-3和其配体的相互作用治疗癌症
KR20210124308A (ko) 2019-01-30 2021-10-14 트루바인딩 아이엔씨. 항-gal3 항체 및 이의 용도
MX2022014786A (es) 2020-05-26 2023-01-16 Truebinding Inc Metodos para tratar enfermedades inflamatorias mediante el bloqueo de galectina-3.
US11919958B2 (en) 2020-08-19 2024-03-05 Xencor, Inc. Anti-CD28 compositions
IL314993A (en) 2022-02-23 2024-10-01 Xencor Inc Anti-cd28 x anti-psma antibodies
WO2024040195A1 (en) 2022-08-17 2024-02-22 Capstan Therapeutics, Inc. Conditioning for in vivo immune cell engineering
WO2024251884A1 (en) 2023-06-09 2024-12-12 Innate Pharma Nk cell engager proteins comprising anti-cd20 and ant-nkp46 antibody, linked to il-2 in treatment of r/r b-nhl
KR20260081298A (ko) * 2023-08-28 2026-06-02 젠코어 인코포레이티드 항-cd20 x 항-cd28 조합 요법
TW202602921A (zh) * 2024-02-09 2026-01-16 大陸商上海岸邁生物科技有限公司 多功能nk細胞接合器
WO2026055280A1 (en) * 2024-09-04 2026-03-12 Sanofi Interleukin 2 (il-2) and cd123 nk cell engager combination therapy

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5229109A (en) 1992-04-14 1993-07-20 Board Of Regents, The University Of Texas System Low toxicity interleukin-2 analogues for use in immunotherapy
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
US6323322B1 (en) 1997-04-30 2001-11-27 Enzon, Inc. Single-chain antigen-binding proteins capable of glycosylation, production and uses thereof
JP4334141B2 (ja) 1998-04-20 2009-09-30 グリカート バイオテクノロジー アクチェンゲゼルシャフト 抗体依存性細胞傷害性を改善するための抗体のグリコシル化操作
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
US7183387B1 (en) 1999-01-15 2007-02-27 Genentech, Inc. Polypeptide variants with altered effector function
HUP0104865A3 (en) 1999-01-15 2004-07-28 Genentech Inc Polypeptide variants with altered effector function
EP2275540B1 (en) 1999-04-09 2016-03-23 Kyowa Hakko Kirin Co., Ltd. Method for controlling the activity of immunologically functional molecule
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
PL213948B1 (pl) 2001-10-25 2013-05-31 Genentech Inc Kompozycje zawierajace glikoproteine, czasteczka kwasu nukleinowego kodujaca te glikoproteine, komórka gospodarza, sposób wytwarzania glikoproteiny, kompozycja do zastosowania do leczenia, zastosowanie kompozycji i zestaw zawierajacy kompozycje
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
PT1534335E (pt) 2002-08-14 2012-02-28 Macrogenics Inc Anticorpos específicos de fcγriib e processos para a sua utilização
JP2004126818A (ja) 2002-09-30 2004-04-22 Toshiba Corp 電子機器システム、電池ユニットおよび電池ユニットの動作制御方法
US7355008B2 (en) 2003-01-09 2008-04-08 Macrogenics, Inc. Identification and engineering of antibodies with variant Fc regions and methods of using same
US7960512B2 (en) 2003-01-09 2011-06-14 Macrogenics, Inc. Identification and engineering of antibodies with variant Fc regions and methods of using same
WO2005040219A1 (en) 2003-10-28 2005-05-06 Novo Nordisk A/S Laminin-5 gamma2-binding peptides, related compositions, and use thereof
WO2005047327A2 (en) 2003-11-12 2005-05-26 Biogen Idec Ma Inc. NEONATAL Fc RECEPTOR (FcRn)-BINDING POLYPEPTIDE VARIANTS, DIMERIC Fc BINDING PROTEINS AND METHODS RELATED THERETO
EP1747237A4 (en) 2004-04-16 2008-05-21 Macrogenics Inc SPECIFIC GAMMA FC ANTIBODIES AND METHODS OF USING THE SAME
CA2565874C (en) 2004-05-10 2017-10-03 Macrogenics, Inc. Humanized fc.gamma.riib-specific antibodies and methods of use thereof
AU2005335714B2 (en) 2004-11-10 2012-07-26 Macrogenics, Inc. Engineering Fc antibody regions to confer effector function
FR2879605B1 (fr) 2004-12-16 2008-10-17 Centre Nat Rech Scient Cnrse Production de formats d'anticorps et applications immunologiques de ces formats
KR20080032065A (ko) 2005-06-03 2008-04-14 제넨테크, 인크. 푸코실화 수준이 조절된 항체의 생성 방법
DK2573114T3 (en) 2005-08-10 2016-07-04 Macrogenics Inc The identification and production of antibodies with variant Fc regions, and methods of using same
JP2009529331A (ja) 2006-03-10 2009-08-20 マクロジェニクス,インコーポレーテッド 変異型重鎖を有する抗体の同定および工学的改変ならびにその使用方法
CA2660592C (en) 2006-05-26 2016-07-12 Macrogenics, Inc. Humanized fc.gamma.riib-specific antibodies and methods of use thereof
EP2032159B1 (en) 2006-06-26 2015-01-07 MacroGenics, Inc. Combination of fcgammariib antibodies and cd20-specific antibodies and methods of use thereof
EP3663318A1 (en) 2008-01-07 2020-06-10 Amgen Inc. Method for making antibody fc-heterodimeric molecules using electrostatic steering effects
TWI507525B (zh) 2009-06-26 2015-11-11 Regeneron Pharma 具天然免疫球蛋白形式之易分離的雙專一性抗體
DK2542256T3 (da) 2010-03-04 2019-08-26 Macrogenics Inc Antistoffer reagerende med b7-h3, immunologisk aktive fragmenter deraf og anvendelser deraf
US9598499B2 (en) 2010-12-30 2017-03-21 Institut National De La Santé Et De La Recherche Médicale (Inserm) Antigen binding formats for use in therapeutic treatments or diagnostic assays
CN105440123B (zh) 2011-02-10 2020-10-09 罗切格利卡特公司 突变体白介素-2多肽
EA201892619A1 (ru) 2011-04-29 2019-04-30 Роше Гликарт Аг Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
RU2682449C2 (ru) 2012-09-19 2019-03-19 Иннейт Фарма Связывающие kir3dl2 агенты
JP6822849B2 (ja) 2014-06-27 2021-01-27 イナート・ファルマ・ソシエテ・アノニムInnate Pharma Pharma S.A. 多重特異的NKp46結合タンパク質
AU2016284871B2 (en) * 2015-06-23 2022-09-29 Innate Pharma Multispecific NK engager proteins
JP6840682B2 (ja) * 2015-06-23 2021-03-10 イナート・ファルマ・ソシエテ・アノニムInnate Pharma Pharma S.A. 多重特異的抗原結合タンパク質
CA3007898A1 (en) 2015-12-28 2017-07-06 Innate Pharma Variable regions for nkp46 binding proteins
US11291721B2 (en) * 2016-03-21 2022-04-05 Marengo Therapeutics, Inc. Multispecific and multifunctional molecules and uses thereof
TWI821192B (zh) 2017-07-11 2023-11-11 美商新索思股份有限公司 非天然核苷酸之導入及其方法
IL321812A (en) 2017-08-03 2025-08-01 Synthorx Inc Cytokine complexes for the treatment of autoimmune diseases
CA3098930A1 (en) 2018-09-21 2020-03-26 Innovent Biologics (Suzhou) Co., Ltd. Novel interleukin-2 and use thereof
JP7778571B2 (ja) 2019-06-05 2025-12-02 アッシャー バイオセラピューティクス, インコーポレイテッド 免疫細胞機能をモジュレートするための変異体インターロイキン-2ポリペプチドと抗原結合分子の融合体
CA3143034A1 (en) 2019-06-14 2020-12-17 Cugene Inc. Novel interleukin-2 variants for the treatment of cancer

Similar Documents

Publication Publication Date Title
Labriola-Tompkins et al. Identification of the discontinuous binding site in human interleukin 1 beta for the type I interleukin 1 receptor.
Takatsu et al. Interleukin 5, a T-cell-derived B-cell differentiation factor also induces cytotoxic T lymphocytes.
Cherwinski et al. Two types of mouse helper T cell clone. III. Further differences in lymphokine synthesis between Th1 and Th2 clones revealed by RNA hybridization, functionally monospecific bioassays, and monoclonal antibodies.
US20210269502A1 (en) Tumor-specific ifna secretion by car t-cells to reprogram the solid tumor microenvironment
Dumoutier et al. IL-TIF/IL-22: genomic organization and mapping of the human and mouse genes
Brown et al. B cell stimulatory factor-1/interleukin-4 mRNA is expressed by normal and transformed mast cells
Wilson et al. Clustering of cytokine genes on mouse chromosome 11.
SE461223B (sv) Mrna och cdna foer humant fibroblastinterferon, foerfarande foer deras framstaellning samt anvaendning daerav
JPS63299A (ja) ヒトg−csfタンパク質の発現
SE465223B (sv) Moget rekombinant-humanleukocytinterferon och foerfarande foer dess framstaellning
US11542318B2 (en) Use of chemokine receptor CXCR5
Liu et al. Mesenchymal stem cell-mediated immunomodulation of recruited mononuclear phagocytes during acute lung injury: a high-dimensional analysis study
Chatchawan et al. Oxynema, a new genus separated from the genus Phormidium (Cyanophyta)
JPH03155795A (ja) マウス・インターロイキン―6レセプター蛋白質
CN1193280A (zh) 用于治疗的cd44基因表达的控制
CN116286844A (zh) 人IL-1R1和人IL-1RAcP多肽片段组合的同源二聚体蛋白质与用途
CN110684787B (zh) 一种斑节对虾糖原合成酶激酶GSK3β基因及其应用
He et al. Abundant members of Scavenger receptors family and their identification, characterization and expression against Vibrio alginolyticus infection in juvenile Larimichthys crocea
CN1198186A (zh) 趋化因子β-8的短形式
CN1040822A (zh) 胃动素样多肽的制备及表达
CN107217068A (zh) 一种提高重组犬干扰素‑α融合蛋白抗病毒活性的方法
Hattori et al. The DNA sequence of human chromosome 21.
CN115093476B (zh) 花鲈II型干扰素IFN-γrel及其受体的抗病毒组合物和应用
Laskov et al. Simultaneous expression of mu‐and gamma‐chain mRNA in cloned murine B‐lymphoma cell lines.
Yasueda et al. Effect of semi-random mutagenesis at the C-terminal 4 amino acids of human interleukin-6 on its biological activity